All times are listed in CEST (Central European Summer Time)

 

Browsing Over 476 Presentations

Sort By
Multidisciplinary Tumour Board

Positioning of treatment of the primary tumour

Lecture Time
14:40 - 15:00
Speakers
  • S. Jabbour (New Brunswick, United States of America)
Session Name
Oligometastatic disease in oncogene addicted NSCLC (ID 32)
Room
Auditorium 1
Date
Wed, 29.03.2023
Time
14:30 - 16:00
Authors
  • S. Jabbour (New Brunswick, United States of America)
Special session

Being an informal carer: Overcoming challenges to their own health and quality of life and facilitating the role

Lecture Time
11:50 - 12:10
Speakers
  • J. Vicente (Kalmar, Sweden)
Session Name
Optimising cancer outcomes through supportive care (Cancer nursing session) (ID 8)
Room
Auditorium 15
Date
Fri, 31.03.2023
Time
10:30 - 12:00
Authors
  • J. Vicente (Kalmar, Sweden)
AstraZeneca - Screen, test & treat: New horizons in early stage NSCLC management (ID 30) Industry Satellite Symposium

IO consolidation after CRT for unresectable NSCLC: From clinical trials to real-world practice

Lecture Time
13:53 - 14:08
Speakers
  • F. McDonald (London, United Kingdom)
Authors
  • F. McDonald (London, United Kingdom)
Session Name
AstraZeneca - Screen, test & treat: New horizons in early stage NSCLC management (ID 30)
Date
Fri, 31.03.2023
Time
12:45 - 14:15
Room
Auditorium 2
Educational session

Challenges in early phase immunotherapy clinical trial design

Lecture Time
17:40 - 18:00
Speakers
  • U. Dafni (Athens, Greece)
Session Name
Challenges and shifting paradigms in clinical trial designs (ID 45)
Room
Auditorium 4
Date
Fri, 31.03.2023
Time
17:00 - 18:30
Authors
  • U. Dafni (Athens, Greece)
Controversy session

Introduction and first vote

Lecture Time
08:00 - 08:10
Speakers
  • L. Hendriks (Maastricht, Netherlands)
Session Name
Is neoadjuvant chemo-immunotherapy superior to adjuvant immunotherapy? (ID 44)
Room
Auditorium 4
Date
Thu, 30.03.2023
Time
08:00 - 09:00
Authors
  • L. Hendriks (Maastricht, Netherlands)
Educational session

Q&A

Lecture Time
11:35 - 11:45
Speakers
  • A. Brunelli (Leeds, United Kingdom)
Session Name
Stage IIIA patients: Surgical and non-surgical treatment in the context of IO (ID 9)
Room
Auditorium 4
Date
Sat, 01.04.2023
Time
10:15 - 11:45
Authors
  • A. Brunelli (Leeds, United Kingdom)
Educational session

HER2 alterations: Past, present and future

Lecture Time
12:15 - 12:35
Speakers
  • A. Passaro (Milan, Italy)
Session Name
Genomic alterations beyond EGFR and ALK (ID 33)
Room
Auditorium 2
Date
Thu, 30.03.2023
Time
11:15 - 12:45
Authors
  • A. Passaro (Milan, Italy)
Controversy session

Introduction and first vote

Lecture Time
17:00 - 17:10
Speakers
  • S. Novello (Orbassano, Italy)
Session Name
Is there a place for conformal PORT in 2023? (ID 48)
Room
Auditorium 2
Date
Thu, 30.03.2023
Time
17:00 - 18:00
Authors
  • S. Novello (Orbassano, Italy)
Special session

Establishing a nationwide lung cancer screening programme: The case of Croatia

Lecture Time
08:50 - 09:10
Speakers
  • S. Karabatic (Zagreb, Croatia)
Session Name
Harnessing the power of screening in lung cancer (Cancer nursing session) (ID 24)
Room
Auditorium 15
Date
Fri, 31.03.2023
Time
08:30 - 10:00
Authors
  • S. Karabatic (Zagreb, Croatia)
Novocure GmbH - The evolving role of tumor treating fields therapy in thoracic oncology (ID 49) Industry Satellite Symposium

Panel discussion: Evolving role of TTFields therapy in solid tumors

Lecture Time
13:35 - 14:05
Speakers
  • A. F. Hottinger (Lausanne, Switzerland)
Authors
  • A. F. Hottinger (Lausanne, Switzerland)
  • C. J. Langer (Philadelphia, United States of America)
  • A. Dovin (Solna, Sweden)
  • J. Sehouli (Berlin, Germany)
Session Name
Novocure GmbH - The evolving role of tumor treating fields therapy in thoracic oncology (ID 49)
Date
Fri, 31.03.2023
Time
12:45 - 14:15
Room
Auditorium 4
Special Symposium

Utility of genotyping in monitoring disease evolution and treatment response

Lecture Time
15:30 - 15:50
Speakers
  • R. Dziadziuszko (Gdansk, Poland)
Session Name
Genotyping in NSCLC: Monitoring, germline alterations, minimal residual disease (ID 36)
Room
Auditorium 2
Date
Fri, 31.03.2023
Time
15:10 - 16:40
Authors
  • R. Dziadziuszko (Gdansk, Poland)
Mirati Therapeutics, Inc. - New frontiers in the treatment of advanced NSCLC (ID 40) Industry Satellite Symposium

Chair’s introduction

Lecture Time
11:30 - 11:35
Speakers
  • S. Peters (Lausanne, Switzerland)
Authors
  • S. Peters (Lausanne, Switzerland)
Session Name
Mirati Therapeutics, Inc. - New frontiers in the treatment of advanced NSCLC (ID 40)
Date
Wed, 29.03.2023
Time
11:30 - 13:00
Room
Auditorium 2